# GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients

> **NCT05316935** · PHASE2,PHASE3 · RECRUITING · sponsor: **Xiaojun Chen** · enrollment: 80 (estimated)

## Conditions studied

- Endometrial Neoplasms
- Atypical Endometrial Hyperplasia
- Progesterone Resistance

## Interventions

- **DRUG:** GnRHa
- **DRUG:** Letrozole 2.5mg
- **DRUG:** Diane-35
- **DRUG:** MET

## Key facts

- **NCT ID:** NCT05316935
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2026-03-30
- **Final completion:** 2027-03-30
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316935

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316935, "GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients". Retrieved via AI Analytics 2026-07-08 from https://api.ai-analytics.org/clinical/NCT05316935. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*